-
公开(公告)号：US20120064101A1
公开(公告)日：2012-03-15
申请号：US13284660
申请日：2011-10-28
申请人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Ping Yuan
发明人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Ping Yuan
IPC分类号： A61K39/00 , C07K14/46 , C07K14/705 , C12N9/14 , G01N33/566 , A61K38/17 , A61P37/04 , C40B30/04 , A61P43/00 , C07H21/04 , A61K38/46
CPC分类号： G01N33/57419 , A61K2039/53 , C07K14/47
摘要： The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumours and HNPCC associated tumours. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumour specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumour cells for prevention and curative treatment of cancers and precancers.
摘要翻译： 本发明涉及可用于检测和治疗与编码微卫星区域中的移码突变相关的病症的化合物和方法。 这些化合物和方法适用于癌症，特别是DNA错配修复缺陷（MMR）散发性肿瘤和HNPCC相关肿瘤。 该化合物可用于检测疾病和治疗如免疫治疗。 诊断方法涉及基于针对针对体液中所述移码多肽的免疫学实体的检测而编码基因编码微卫星区域中的移码突变的与移码多肽相关的病症的诊断和预后评估。 关于癌症的治疗，本发明涉及使用具有肿瘤特异性移码肽的组合混合物的免疫治疗以引发特异性针对肿瘤细胞的细胞毒性T细胞应答以预防和治疗癌症和预防剂的方法。
-
2.发明授权公开(公告)号：US07569538B2
公开(公告)日：2009-08-04
申请号：US11433386
申请日：2006-05-15
CPC分类号： A61K39/0011 , A61K2039/53
摘要： The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.
摘要翻译： 本发明涉及一种药物组合物，其包含细胞周期调节蛋白和/或编码该细胞周期调节蛋白和/或可表达核酸的量，其适合个体免疫个体对癌症及其初级阶段和普通助剂和/或 使用细胞周期调节蛋白和/或编码该细胞周期调控蛋白的可表达核酸来免疫个体免受癌症及其初步阶段的侵害。
-
公开(公告)号：US08946171B2
公开(公告)日：2015-02-03
申请号：US12500458
申请日：2009-07-09
CPC分类号： A61K39/0011 , A61K2039/53
摘要： The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.
-
公开(公告)号：US08821864B2
公开(公告)日：2014-09-02
申请号：US13284660
申请日：2011-10-28
申请人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Ping Yuan
发明人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Ping Yuan
IPC分类号： A61K39/395
CPC分类号： G01N33/57419 , A61K2039/53 , C07K14/47
摘要： The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for prevention and curative treatment of cancers and precancers.
摘要翻译： 本发明涉及可用于检测和治疗与编码微卫星区域中的移码突变相关的病症的化合物和方法。 这些化合物和方法适用于癌症，特别是DNA错配修复缺陷（MMR）散发性肿瘤和HNPCC相关肿瘤。 该化合物可用于检测疾病和治疗如免疫治疗。 诊断方法涉及基于针对针对体液中所述移码多肽的免疫学实体的检测而编码基因编码微卫星区域中的移码突变的与移码多肽相关的病症的诊断和预后评估。 关于癌症的治疗，本发明涉及使用具有肿瘤特异性移码肽的组合混合物的免疫治疗以引发特异性针对肿瘤细胞的细胞毒性T细胞应答以预防和治疗癌症和预防剂的方法。
-
公开(公告)号：US08053552B2
公开(公告)日：2011-11-08
申请号：US10511698
申请日：2003-04-17
申请人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Ping Yuan
发明人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Ping Yuan
CPC分类号： G01N33/57419 , A61K2039/53 , C07K14/47
摘要： The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds disclosed in the invention are useful for detection of disorders and in therapy such as e.g. immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for use in prevention as well as in curative treatment of cancers and precancers.
摘要翻译： 本发明涉及可用于检测和治疗与编码微卫星区域中的移码突变相关的病症的化合物和方法。 这些化合物和方法适用于癌症，特别是DNA错配修复缺陷（MMR）散发性肿瘤和HNPCC相关肿瘤。 本发明中公开的化合物可用于疾病的检测和治疗中的检测。 免疫治疗。 诊断方法涉及基于针对针对体液中所述移码多肽的免疫学实体的检测而编码基因编码微卫星区域中的移码突变的与移码多肽相关的病症的诊断和预后评估。 关于癌症的治疗，特别是DNA错配修复缺陷（MMR）散发性肿瘤和HNPCC相关肿瘤的治疗，本发明涉及使用具有肿瘤特异性移码肽的组合混合物的免疫治疗来引发细胞毒性T细胞应答的方法 针对肿瘤细胞用于预防以及治疗癌症和预防药物。
-
6.发明申请公开(公告)号：US20110064770A1
公开(公告)日：2011-03-17
申请号：US12500458
申请日：2009-07-09
CPC分类号： A61K39/0011 , A61K2039/53
摘要： The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.
摘要翻译： 本发明涉及一种药物组合物，其包含细胞周期调节蛋白和/或编码该细胞周期调节蛋白和/或可表达核酸的量，其适合个体免疫个体对癌症及其初级阶段和普通助剂和/或 使用细胞周期调节蛋白和/或编码该细胞周期调控蛋白的可表达核酸来免疫个体免受癌症及其初步阶段的侵害。
-
公开(公告)号：US20060210591A1
公开(公告)日：2006-09-21
申请号：US11433386
申请日：2006-05-15
CPC分类号： A61K39/0011 , A61K2039/53
摘要： The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.
-
公开(公告)号：US20050239070A1
公开(公告)日：2005-10-27
申请号：US10511698
申请日：2003-04-17
申请人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Yuan
发明人： Magnus Von Knebel-Doeberitz , Johannes Gebert , Michael Linnebacher , Stefan Woerner , Ruediger Ridder , Peer Bork , Yan Yuan
IPC分类号： C07K14/47 , C12Q1/68 , C07H21/04 , C07K14/82 , G01N33/574
CPC分类号： G01N33/57419 , A61K2039/53 , C07K14/47
摘要： The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds disclosed in the invention are useful for detection of disorders and in therapy such as e.g. immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for use in prevention as well as in curative treatment of cancers and precancers.
摘要翻译： 本发明涉及可用于检测和治疗与编码微卫星区域中的移码突变相关的病症的化合物和方法。 这些化合物和方法适用于癌症，特别是DNA错配修复缺陷（MMR）散发性肿瘤和HNPCC相关肿瘤。 本发明中公开的化合物可用于疾病的检测和治疗中的检测。 免疫治疗。 诊断方法涉及基于针对针对体液中所述移码多肽的免疫学实体的检测而编码基因编码微卫星区域中的移码突变的与移码多肽相关的病症的诊断和预后评估。 关于癌症的治疗，特别是DNA错配修复缺陷（MMR）散发性肿瘤和HNPCC相关肿瘤的治疗，本发明涉及使用具有肿瘤特异性移码肽的组合混合物的免疫治疗来引发细胞毒性T细胞应答的方法 针对肿瘤细胞用于预防以及治疗癌症和预防药物。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.018 秒)
